We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $20.21 as of October 8th. TEVA’s trailing and forward P/E were 872.00 and 7.06 respectively according to Yahoo Finance.
Teva Pharmaceutical Industries (TEVA) is emerging as a compelling turnaround story, transitioning from a debt-laden generics player to a focused branded and specialty company with momentum in neuroscience. Market activity underscores this shift, with institutional investors showing significant bullish positioning in October 2025 call options. Technically, the stock has recovered past $20, holding above key moving averages, signaling a constructive setup.
Central to Teva’s transformation is Ajovy, its anti-CGRP therapy for migraine prevention, which continues to deliver steady growth with expected quarterly sales around $70 million. Ajovy is establishing a durable presence in a large and expanding migraine market, benefiting from improved access dynamics and flexible dosing options, giving it a long runway despite competition from Lilly and Amgen.
Even more promising is Teva’s long-acting injectable (LAI) olanzapine program, TEV-749. Phase 3 SOLARIS trial data demonstrated robust efficacy across schizophrenia endpoints and, importantly, no instances of the historical post-injection delirium/sedation syndrome due to Teva’s SteadyTeq® technology. With LAIs currently underpenetrated, TEV-749 alongside UZEDY could capture significant market share, potentially generating $1.5–2.0 billion in peak sales and reshaping Teva’s branded psychiatry franchise.
Financially, Teva is strengthening, with 2025 revenues projected near $17 billion, EPS around $2.60, EBIT margins approaching 27%, and free cash flow growth. Net debt has declined from over $18 billion to approximately $11 billion, with further deleveraging expected, bringing leverage close to 1x Net Debt/EBITDA. Trading at roughly 7x 2025 earnings, Teva offers a rare combination of value and growth.
With steady performance from Ajovy and Austedo and a potential blockbuster in TEV-749, Teva is moving beyond its generics legacy. The convergence of pipeline progress, technical strength, and improving fundamentals positions the stock for a potential re-rating, making the current price an attractive entry point for investors seeking both growth and value.
Previously we covered a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in May 2025, which highlighted the company’s shift from generics toward branded and specialty medicines, strong revenue growth, and operational improvements. The company’s stock price has appreciated approximately by 20% since our coverage. The thesis still stands as momentum in neuroscience continues. Kontra emphasizes TEV-749 and technical strength as new catalysts.
